Complex interactions underlie racial disparity in the risk of developing Alzheimer's disease dementia.

Black or African American / statistics & numerical data Aged Alzheimer Disease / diagnosis Apolipoprotein E4 / genetics Body Mass Index Female Humans Male Risk Factors White People / statistics & numerical data
competing risk survival model interactions racial disparity risk of Alzheimer's disease

Journal

Alzheimer's & dementia : the journal of the Alzheimer's Association
ISSN: 1552-5279
Titre abrégé: Alzheimers Dement
Pays: United States
ID NLM: 101231978

Informations de publication

Date de publication:
04 2020
Historique:
received: 28 06 2019
revised: 31 12 2019
accepted: 03 01 2020
pubmed: 19 2 2020
medline: 22 1 2021
entrez: 19 2 2020
Statut: ppublish

Résumé

We aim to determine racial disparities and their modifying factors in risk for Alzheimer's disease (AD) dementia among cognitively normal individuals 65 years or older. Longitudinal data from the National Alzheimer's Coordinating Center Uniform Data Set on 1229 African Americans (AAs) and 6679 whites were analyzed for the risk of AD using competing risk models with death as a competing event. Major AD risk factors modified racial differences which, when statistically significant, occurred only with older age among APOE ε4 negative individuals, but also with younger age among APOE ε4 positive individuals. The racial differences favored AAs among individuals with body mass index (BMI) < 30, but whites among individuals with a high BMI (≥ 30), and were additionally modified by sex, education, hypertension, and smoking status. The presence, direction, and relative magnitude of racial disparity for AD represent an interactive function of major AD and cerebrovascular risk factors.

Identifiants

DOI: 10.1002/alz.12060 PMID: 32067357 PMC: PMC7259475
pubmed: 32067357
doi: 10.1002/alz.12060
pmc: PMC7259475
mid: NIHMS1591519
doi:

Substances chimiques

Apolipoprotein E4 0

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

589-597

Subventions

Organisme : NIA NIH HHS
ID : P50 AG005142
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG066515
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG016573
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG010161
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG025688
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005133
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005138
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG047366
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG010129
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG019610
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG028383
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG033514
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG013854
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG053760
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG066444
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG010124
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG023501
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005131
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG010133
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG016574
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005146
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG0399131
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG035982
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG008702
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG016976
Pays : United States
Organisme : NIA NIH HHS
ID : RF1 AG053550
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG003991
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG008051
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005681
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG013846
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG026276
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG047270
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005136
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG049638
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG012300
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG047266
Pays : United States
Organisme : NIA NIH HHS
ID : R01AG053550
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005134
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG008017
Pays : United States

Informations de copyright

© 2020 the Alzheimer's Association.

Références

J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Alzheimers Dement. 2016 Mar;12(3):216-24
pubmed: 26874595
Alzheimers Res Ther. 2017 Nov 2;9(1):88
pubmed: 29096697
J Natl Med Assoc. 1989 Jun;81(6):644-52
pubmed: 2746686
Arch Neurol. 2001 Sep;58(9):1395-402
pubmed: 11559310
Am J Geriatr Psychiatry. 2005 Nov;13(11):959-67
pubmed: 16286439
Alzheimers Dement (N Y). 2018 Mar 08;4:150-160
pubmed: 29955659
Neurology. 1993 Nov;43(11):2412-4
pubmed: 8232972
Arch Neurol. 2007 Mar;64(3):343-9
pubmed: 17210801
Alzheimer Dis Assoc Disord. 2004 Oct-Dec;18(4):270-7
pubmed: 15592144
Alzheimers Dement. 2016 Jun;12(6):669-77
pubmed: 27094726
Ann Neurol. 2010 Jan;67(1):122-31
pubmed: 20186853
JAMA Neurol. 2019 Mar 1;76(3):264-273
pubmed: 30615028
Arch Neurol. 1985 Aug;42(8):740-3
pubmed: 4026605
Neurology. 2016 Apr 19;86(16):1499-506
pubmed: 27009258
N Engl J Med. 2012 Aug 30;367(9):795-804
pubmed: 22784036
Alzheimer Dis Assoc Disord. 2018 Jan-Mar;32(1):10-17
pubmed: 29240561
Alzheimers Dement. 2017 Jan;13(1):8-19
pubmed: 27583651
Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4):210-6
pubmed: 17132964
J Neurosci. 1996 Jul 15;16(14):4491-500
pubmed: 8699259
Lancet Neurol. 2010 Jan;9(1):119-28
pubmed: 20083042
J Clin Epidemiol. 1998 Jul;51(7):587-95
pubmed: 9674666
J Am Geriatr Soc. 2004 Feb;52(2):195-204
pubmed: 14728627
Neurology. 2001 Jan 9;56(1):49-56
pubmed: 11148235
Neuroimage Clin. 2017 Sep 21;16:659-667
pubmed: 29868439
Am J Epidemiol. 1984 Sep;120(3):331-41
pubmed: 6332530
Neurology. 2008 Apr 1;70(14):1163-70
pubmed: 18003939
Nature. 2017 Jul 12;547(7662):153-155
pubmed: 28703214
Neurology. 2016 Aug 2;87(5):473-80
pubmed: 27371485

Auteurs

Chengjie Xiong (C)

Division of Biostatistics, Washington University School of Medicine, St. Louis, Missouri, USA.
Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.

Jingqin Luo (J)

Division of Biostatistics, Washington University School of Medicine, St. Louis, Missouri, USA.
Division of Public Health Sciences, Department of Surgery, Washington University School of Medicine, St. Louis, Missouri, USA.
Siteman Cancer Center Biostatistics Core, Washington University School of Medicine, St. Louis, Missouri, USA.

Dean Coble (D)

Division of Biostatistics, Washington University School of Medicine, St. Louis, Missouri, USA.
Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.

Folasade Agboola (F)

Division of Biostatistics, Washington University School of Medicine, St. Louis, Missouri, USA.
Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.

Walter Kukull (W)

Department of Epidemiology, University of Washington, Seattle, Washington, USA.
National Alzheimer's Coordinating Center, University of Washington, Seattle, Washington, USA.

John C Morris (JC)

Knight Alzheimer Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA.
Department of Neurology, Washington University School of Medicine, St. Louis, Missouri, USA.
Departments of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Nord-Américains › Groupes de population aux États-Unis › Populations d'origine continentale › Noir ou Africain Américain › Complex interactions underlie racial disparity...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Complex interactions underlie racial disparity...
questionsmedicales.fr › Troubles mentaux › Troubles neurocognitifs › Démence › Maladie d'Alzheimer › Complex interactions underlie racial disparity...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Lipoprotéines › Apolipoprotéines › Apolipoprotéines E › Apolipoprotéine E4 › Complex interactions underlie racial disparity...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Mesures épidémiologiques › Biométrie › Anthropométrie › Indice de masse corporelle › Complex interactions underlie racial disparity...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Complex interactions underlie racial disparity...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Facteurs de risque › Complex interactions underlie racial disparity...
questionsmedicales.fr › Personnes › Blancs › Complex interactions underlie racial disparity...